|
A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on… |
rosiglitazone |
49653/096 |
|
Diabetes Mellitus, Type 2 |
Phase 3 |
|
|
|
|
Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
July 2015 |